The CDPath prognostic tool gives Crohn's patients risk scores for serious complications within three years, so they can make more informed treatment decisions.
FDA Approves Takeda's Exkivity With Thermo Fisher CDx for EGFR Exon20 Insertion-Positive NSCLC
This is the first time the FDA has approved a drug specifically for NSCLC patients who harbor rare EGFR Exon20 insertion mutations.
Takeda Pharmaceutical, Rady Children's Partner on Rare Genetic Disease Drug Development
The partners will use data derived from whole-genome sequencing to discover and develop treatments for rare child-onset genetic diseases.
FDA Approves FoundationOne CDx for Takeda's ALK-Inhibitor
The agency approved Foundation Medicine's tissue-based, next-generation sequencing test to identify patients with ALK-positive NSCLC eligible for Alunbrig.
Evotec, Takeda Pharmaceuticals Partner on RNA-Targeting Drug Development
The companies will work together to identify and develop small molecule drugs against RNA targets that fit within Takeda's disease areas of focus.